ArticleBMC medical imaging2026
Multimodal MRI and machine learning for identifying depression in cerebral small vessel disease: a multicenter study.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThis study sought to evaluate the effectiveness of a machine learning (ML) model utilizing multimodal MRI in distinguishing cerebral small vessel disease (CSVD) patients with depression (CSVD + D) from those without depression (CSVD − D). MATERIALS AND
methodsThis retrospective study involved 198 participants from three centers, who were divided into training (n = 113; CSVD + D = 56, CSVD − D = 57), external validation 1 (n = 85; CSVD + D = 31, CSVD − D = 54), and 2 (n = 102; CSVD + D = 39, CSVD − D = 63) cohorts. Structural, functional, and diffusion tensor imaging was used to extract features, which were utilized to construct ML models based on nine ML classifiers. The efficacy of the models was evaluated through the receiver operating characteristic (ROC) analysis. SHapley additive explanations (SHAP) analysis provided deep insights into the model’s interpretability.
resultsTwelve features from multimodal MRI were finally identified. The eXtreme Gradient Boosting (XGBoost) classifier performed the best. The XGBoost-based multimodal model integrating features from all three modalities achieved high diagnostic performance, with areas under the ROC curves of 0.958, 0.893, and 0.917 in the training, external validation 1 and 2 cohorts, respectively, and accuracies of 0.929, 0.871, and 0.853. The SHAP results revealed that the key contributing features included elevated amplitude of low-frequency fluctuations in the superior frontal gyrus and reduced fractional anisotropy in the default mode network.
conclusionIntegrating multimodal MRI and ML may improve the classification performance for identifying CSVD + D, suggesting the potential value of multimodal imaging markers in the assessment of CSVD-related depressive symptoms. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.